
For research use only. We do not supply to patients.
For pharmaceutical-grade products or other inquiries, please contact our experts.
Researchers investigated whether the maximum allowed human dose of aspartame (40 mg/kg/day) affects kidney function or induces oxidative stress, addressing concerns about its metabolites causing renal damage. Researchers used ICR mice fed folate-deficient diets to mimic human metabolism, dividing them into control, aspartame-only, folate-deficient, and combined treatment groups. After eight weeks of oral aspartame administration, no significant differences were observed in serum creatinine, blood urea nitrogen, urinary biomarkers, or kidney histology between groups. Immunohistochemical analysis also showed no changes in oxidative stress markers (SOD and 4-HNE). These results indicate that approved aspartame doses do not cause renal dysfunction or oxidative stress in this human-metabolism-mimicking model, contradicting some previous high-dose rodent studies but aligning with clinical data. Limitations include undetermined serum folate levels in test groups and exclusive focus on kidney effects. The findings support aspartame’s renal safety at regulatory-approved levels but warrant further multi-organ and long-term research.
Fig. 2 Evaluation of morphological changes in the kidneys. (Torigoe K, et al. 2024)
References
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
All our products are chemicals for research purposes only. We do not supply for human or veterinary applications.
Privacy Policy | Cookie Policy Copyright © Protheragen. All Rights Reserved.
